19 May 2013
Keywords: Novartis, Onbrez, Spiriva, Lung function, COPD
Article | 11 February 2011
Swiss drug major Novartis (NOVN: VX) yesterday announced that two Phase III studies show that patients with chronic obstructive pulmonary ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
11 February 2011
10 February 2011
17 May 2013
© 2013 thepharmaletter.com